GLP-1s and sudden vision loss: New guidance urges caution, not alarm

Clinical Takeaway: Patients taking GLP-1 receptor agonists who develop sudden painless vision loss should be evaluated immediately by an ophthalmologist, but clinicians should not automatically stop therapy without shared decision-making across the care team.

A May 2026 consensus statement from the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology concludes that current evidence suggests a possible association between semaglutide and non-arteritic anterior ischemic optic neuropathy (NAION), a rare but often permanent cause of optic nerve–related vision loss. However, the groups emphasize that the absolute risk remains low and that causality has not been established.

The statement reviews a rapidly evolving evidence base dominated by retrospective database and claims studies, many of which are limited by coding inaccuracies, confounding, selection bias, and inconsistent ophthalmologic follow-up. Some studies suggest roughly a twofold increased risk, while others find no association. NAION itself is rare, with baseline annual incidence estimated at 2.3 to 10.2 cases per 100,000 people.

The authors caution against reflexively discontinuing GLP-1 RA therapy, even after NAION, because stopping treatment may pose substantial metabolic or cardiovascular risks for some patients. Instead, they recommend individualized risk-benefit discussions involving the patient, ophthalmologist, primary care clinician, endocrinologist, and other relevant specialists.

An especially useful message from the statement: “Even a several-fold elevation in relative risk is only a small absolute risk difference.” That framing may help clinicians counsel patients amid heightened concern about GLP-1 safety.

Patients with prior NAION or unexplained vision loss in one eye should be informed about the possible risk before starting or continuing therapy. For other GLP-1 RAs, including tirzepatide, evidence remains insufficient, so clinicians should not assume the concern is limited to semaglutide.

Source: North American Neuro-Ophthalmology Society and American Academy of Ophthalmology. May 2026. Glucagon-like peptide-1 receptor agonists and the risk of non-arteritic anterior ischemic optic neuropathy: A consensus statement by NANOS and the American Academy of Ophthalmology